
Crispr Therapeutics (CRSP) • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold CRSP in your mock portfolio yet.
Crispr Therapeutics remains unprofitable, as reflected in its negative EPS and PE ratio. The current financial profile suggests the company is still in an investment and development phase rather than a cash‑generating phase, which heightens risk and dependence on future clinical and commercial milestones.
The stock has gained 9.3% over the last month, showing short‑term positive momentum. However, it still trades below its 200‑day moving average, suggesting the longer‑term trend is not yet convincingly bullish.
Alternative data shows modest but positive operational and engagement signals. Rising job openings and incremental growth in LinkedIn followers suggest cautious expansion and sustained professional interest, while web traffic and stable social media followings indicate a steady baseline of attention.
Overall sentiment on Crispr Therapeutics is neutral: alternative data and recent price action show improving interest and momentum, but the company’s lack of profitability and a price still below its 200‑day moving average temper the outlook. The stock remains a high‑risk, high‑reward play driven largely by expectations for future clinical and commercial success.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started